Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMUR1MN)

• Drug Name: CD19-CAR and CD28-CAR T Cells Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Acute lymphoblastic leukaemia	2A85	Phase 1	[1]

• Cross-matching ID: TTD Drug ID: DMUR1MN

Molecule-Related Drug Atlas

Drug(s) Targeting B-lymphocyte surface antigen B4 (CD19)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tisagenlecleucel	DMM9BJD	Acute lymphoblastic leukaemia	2A85	Approved	[2]
Blinatumomab	DMGECIJ	Acute lymphoblastic leukaemia	2A85	Approved	[3]
Axicabtagene ciloleucel	DMYHN59	Diffuse large B-cell lymphoma	2A81	Approved	[4]
Lisocabtagene maraleucel	DMP45ME	Large B-cell lymphoma	2A81	Approved	[5]
Inebilizumab	DMI0RHA	Neuromyelitis optica spectrum disorder	8E4A.0	Approved	[6]
Tecartus	DMYQCWT	Mantle cell lymphoma	2A85.5	Approved	[7]
Loncastuximab tesirine	DMXSVGI	Diffuse large B-cell lymphoma	2A81	Approved	[8]
Obexelimab	DMVIC4J	IgG4 related disease	4A43.0	Phase 3	[9]
MOR-208	DMDQOWT	Diffuse large B-cell lymphoma	2A81	Phase 2/3	[10]
CART-19	DMST3FM	Acute lymphoblastic leukaemia	2A85	Phase 2/3	[11]

Drug(s) Targeting T-cell-specific surface glycoprotein CD28 (CD28)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Belatacept	DMXLYQF	Kidney transplant rejection	NE84	Approved	[12]
AB-103	DMPDQ8T	Necrotizing soft tissue infection	1B71	Phase 3	[13]
Lulizumab pegol	DMGWZ93	Systemic lupus erythematosus	4A40.0	Phase 2	[14]
REGN5678	DM0Y6WU	Prostate cancer	2C82.0	Phase 1/2	[15]
AU101	DMLAKPI	Osteosarcoma	2B51	Phase 1/2	[16]
REGN5668	DMH1UV5	Ovarian cancer	2C73	Phase 1/2	[17]
SAR442257	DMXD5QP	Malignant neoplasm	2A00-2F9Z	Phase 1	[18]
CD28 and CD137 CAR-T Cells	DMFGQXB	Acute lymphoblastic leukaemia	2A85	Phase 1	[19]
RO7443904	DMSWZNU	Non-hodgkin lymphoma	2B33.5	Phase 1	[20]
RG6333	DM1BRF2	Non-hodgkin lymphoma	2B33.5	Phase 1	[21]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
B-lymphocyte surface antigen B4 (CD19)	TTW640A	CD19_HUMAN	CAR-T-Cell-Therapy(Dual specific)	[1]
T-cell-specific surface glycoprotein CD28 (CD28)	TTQ13FT	CD28_HUMAN	CAR-T-Cell-Therapy(Dual specific)	[1]

References

• [1] ClinicalTrials.gov (NCT02146924) Cellular Immunotherapy in Treating Patients With High-Risk Acute Lymphoblastic Leukemia
• [2] 2017 FDA drug approvals.Nat Rev Drug Discov. 2018 Feb;17(2):81-85.
• [3] 2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81.
• [4] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services
• [5] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services.
• [6] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020
• [7] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services.
• [8] Final results of a phase 1 study of loncastuximab tesirine in relapsed/refractory B-cell non-Hodgkin lymphoma. Blood. 2021 May 13;137(19):2634-2645.
• [9] Emerging B-Cell Therapies in Systemic Lupus Erythematosus. Ther Clin Risk Manag. 2021 Jan 14;17:39-54.
• [10] A phase 1 trial of the Fc-engineered CD19 antibody XmAb5574 (MOR00208) demonstrates safety and preliminary efficacy in relapsed CLL. Blood. 2014 Dec 4;124(24):3553-60.
• [11] ClinicalTrials.gov (NCT03027739) CART-19 Cells For MRD Positive CD19+ ALL
• [12] New developments in immunosuppressive therapy for heart transplantation. Expert Opin Emerg Drugs. 2009 Mar;14(1):1-21.
• [13] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [14] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [15] Clinical pipeline report, company report or official report of Regeneron Pharmaceuticals.
• [16] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [17] ClinicalTrials.gov (NCT04590326) Phase 1/2 Study of REGN5668 (MUC16xCD28, a Costimulatory Bispecific) Administered in Combination With Cemiplimab or REGN4018 (MUC16xCD3). U.S.National Institutes of Health.
• [18] Clinical pipeline report, company report or official report of Sanofi.
• [19] ClinicalTrials.gov (NCT02186860) Chimeric Antigen Receptor (CAR)-Modified T Cell Therapy in Treating Patients With Acute Lymphoblastic Leukemia
• [20] Clinical pipeline report, company report or official report of Genentch
• [21] Clinical pipeline report, company report or official report of Roche